- |||||||||| INT-2104 / Interius BioTherap
Targeted In Vivo Generation of CAR T and NK Cells Utilizing an Engineered Lentiviral Vector Platform (Marriott Marquis - Marriott Grand) - Nov 3, 2023 - Abstract #ASH2023ASH_4889;
Taken together, these data suggest that intravenous delivery of INT2104 will be both safe and effective, providing a faster, cheaper, and more accessible option for treatment of B cell malignancies. Ongoing efforts include a GLP Toxicology study to enable IND submission in 2Q2024.
- |||||||||| INT-2104 / Interius BioTherap
Targeted in vivo generation of CAR T and NK cells utilizing an engineered lentiviral vector platform (Exhibit Hall B) - Sep 27, 2023 - Abstract #SITC2023SITC_1504;
INT2104 administration to mice bearing an established B cell tumor also resulted in B cell aplasia, with complete tumor ablation seen in all treated mice across a 15-fold range in dosing, including a dose matching the proposed first-in-human dose in TU/kg. Conclusions These preclinical data suggest that intravenous delivery of INT2104 will be both safe and effective, supporting plans to continue development and transition into the clinic.
|
